

STATUS OF THE CLAIMS

Claims 1 to 46 (Currently cancelled)

47. (New) A method of treating an ocular condition with a therapeutically effective alpha 2 adrenergic receptor agonist component comprising an agent selected from the group consisting of 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, a salt thereof, and an ester thereof comprising:
- a) dissolving said agent at a pH above about 7.0 in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered; and
 - b) administering said agent to the eye of said patient.
48. (New) The method of claim 1 in which the concentration of said agent is about 0.15% or less.
49. (New) The method of either one of claims 1 or 2 in which said component comprises a solubility-enhancing component.
50. (New) The method of claim 3 in which said component comprises a preservative.
51. (New) The method of claim 4 in which said preservative comprises a quaternary ammonium polymeric preservative.
52. (New) The method of claim 5 in which said preservative comprises an oxidative preservative.
53. (New) The method of either one of claims 1 or 2 in which said component comprises a preservative.

54. (New) The method of claim 7 in which said preservative comprises a quaternary ammonium polymeric preservative.
55. (New) The method of claim 8 in which said preservative comprises an oxidative preservative.
56. (New) The method of anyone of claims 1, 2 or 3 in which said ocular condition is associated with high intraocular pressure.